That is to say, NPC patients in subtype 1 showed a low triglyceride synthesis (lower expression of AGPAT1 and DGAT1) and high triglyceride degradation (higher expression of ATGL, HSL, and MGL) (p < 0.05), and reversely, NPC patients in subtype 2 showed a high triglyceride synthesis (higher expression of AGPAT1 and DGAT1) and low triglyceride degradation (lower expression of ATGL, HSL, and MGL) (p < 0.05) (Figure 8C). This evidence concerns the gene PNPLA2 and nasopharyngeal carcinoma.